AstraZeneca seeks to halt Apotex's US sales of generic Pulmicort
This article was originally published in Scrip
Executive Summary
AstraZeneca has asked a judge in the US District Court for the District of New Jersey to issue a temporary order that would block Apotex from selling its version of the branded asthma treatment Pulmicort Respules (budesonide inhalation suspension, BIS) in the US.